Signal intensity (SI) enhancement patterns on T1W images can be evaluated by two different analysis techniques: Semi-quantitative techniques describe the shape of the SI vs. time curve, its onset time, gradient of upslope of enhancement curves, maximum SI and washout gradient. Semi-quantitative methods have the advantage of being simple to perform and enable the straightforward calculation of SI changes. However, this method depends on SI which is notoriously dependent on scanning conditions (e.g., MRI vendor, pulse sequence, scaling). In order to avoid these issues SI should be converted into Gd concentration by applying a T1 map to the precontrast tumor images. Fig. 2) (4) . Physiologically, the value of K trans is tissue dependent; K trans will indicate the tissue perfusion per unit volume, if the contrast uptake of the tissue is flow limited; on the other hand, K trans the tumor, such as an artery or muscle for normalization (3) . Quantity of the injected contrast material should be standardized according to the patient's body weight and preferentially should be injected at a constant rate with a power injector. In our institution, we perform DCE-MRI on a 1.5 Tesla magnet (except for brain and prostate, for which we use a 3 Tesla magnet) using 3D spoiled gradient echo sequences. The imaging parameters for various body parts are summarized in Table. After injection, serial image sets are obtained at temporal resolutions ranging indicates the tissue permeability, if the uptake is permeability limited. In majority of tumors, K trans indicates a combination of both flow and permeability properties of the tissue and high K trans values usually reflect both high permeability and high perfusion. This is a fundamental limitation of DCE-MRI, namely the parameters it generates are inherently ambiguous with regard to their physiologic significance. Size of the contrast agent used may also affect K trans value; with macromolecular contrast agents (albumin-Gd-DTPA, dextran-Gd complexes, Gd-viral particles, Gd-liposomes, Gd-dendrimers etc.) K trans decreases reflecting the permeability status of the tissue for larger macromolecules (5). Since tumor vessels tend to have larger pore sizes than normal vessels, DCE-MRI with macromolecular contrast agents may be more definitive for tumor vs. other conditions such as inflammation. However, a limitation of DCE-MRI with macromolecules is that the overall enhancement is reduced leading to signal to noise ratio (SNR) reductions. The arterial input function (AIF) can be used in conjunction with a two compartment model to insure that the DCE parameters are not influenced by contrast injection rates or the cardiovascular condition of the patient. The AIF optimizes the kinetic analysis by measuring the signal from an artery near the tumor and adjusting the results according to the quality of the AIF. If, however, there are artifacts introduced during acquisition of the AIF, it can propagate additional errors into the analysis (Fig. 3 ) (6). 
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Clinical applications
DCE-MRI has been used for several clinical situations including for the initial diagnosis and staging of tumors (7) (8) (9) . Recently DCE-MRI has been used as a biomarker for monitoring response to conventional chemotherapy and/or antiangiogenic therapy, as well as to radiotherapy and embolotherapy for various cancer types such as breast, prostate, colon, and gynecologic malignancies (10) (11) (12) (13) (14) (15) (16) (17) (18) . These studies employing DCE-MRI underscore its potential as a noninvasive biomarker for tumor angiogenesis but further clinical studies in larger patient populations with appropriate validation are needed (Figs. 4-6 ).
Challenges
Implementation of DCE-MRI into clinical imaging protocols poses several challenges. DCE-MRI is being performed more frequently than it was 5 years ago, but there is currently no consensus on which imaging protocol should be used. Moreover, institutions often use their own analysis tool to evaluate the data and greater standardization for quantification is needed. It is critical that repeatability and reproducibility studies be performed to determine the magnitude of the effect that can be measured. For instance, it is not uncommon for two DCE-MRI studies to vary in their results by 20%. In that case, a 40% drug effect is needed to measure a blood flow or permeability difference after therapy. DCE-MRI is also limited in organs with physiologic motion such as the lungs and liver, and breath holding, deformation registration or navigator pulses may be needed to correct this (19, 20) . Importantly, there is no adequate validation methodology for DCE-MRI, specifically for assessing the response to antiangiogenic treatment, since DCE-MRI is a "live" physiologic assay and many of the in vitro assays (e.g., mean vascular density [MVD] ) are "static". Despite its limitations, MVD based on factor VIII, CD34 staining, vascular maturation index, quantification of serum and tumoral VEGF and other angiogenic mediators has been used to validate DCE-MRI. The tumor vasculature is intrinsically heterogeneous and, as a result, whole tumor regions of interest (ROIs) may not demonstrate responses to antiangiogenic therapy that occur in some parts of the tumor but not in other parts (6) . Finally, DCE-MRI may not be feasible for some patient groups, especially individuals with renal failure (due to the risk of nephrogenic systemic fibrosis), those with implanted metallic devices (cardiac pacemakers, prosthetic valves, intracranial aneurysmal clips, shrapnel injury) and those with severe claustrophobia.
Future directions
Although DCE-MRI is not a perfect test for angiogenesis, it is nonetheless a promising and readily available tool, which can serve as a biomarker for monitoring response to angiogenic inhibitor therapies. DCE-MRI with low molecular weight contrast agents can be readily integrated into the clinical work flow and can be considered an "off-the-shelf" technique. Comparisons between centers, however, may be limited. On the other hand, performing DCE-MRI with macromolecular contrast agents, which do not leak as easily as low molecular weight agents, may be more specific for tumor angiogenesis and may therefore provide better response assessment to therapy. Moreover, "selective" targeted DCE-MRI can be potentially performed by targeting epitopes expressed specifically on areas of activated endothelium found at sites of angiogenesis; integrins are the most studied among those target epitopes and although it is a relatively new DCE-MRI approach, several preclinical research studies have focused on exploiting this target as an imaging biomarker.
Conclusion
Angiogenesis is a key step in tumor growth and metastatic spread. Recently DCE-MRI has emerged as a functional method for the assessment of angio- 
